SENS Stock: Senseonics is a game changer for glucose monitoring

Senseonics (SENS) is a medical device startup company in USA developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease.

Utilizing breakthrough fluorescence sensing technology, Senseonics’ continuous glucose monitoring (CGM​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.

The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Being able to have real-time data and alerts about glucose levels can be life saving, keep in mind diabetes is the nation’s seventh-leading cause of death, accounting for more than 79,000 deaths annually. It also contributes to deaths from heart disease and stroke which are the the fifth-leading causes of death, respectively. There are three major types of diabetes: type 1, type 2, and gestational. Type 2 diabetes accounts for 90 to 95 percent of all cases. Eversense aims to keep that safely under control.

They already have FDA APPROVAL for the 90 days monitoring sensor, currently waiting for the new device for 180 days monitoring to be approved hopefully in Q1 2021, you can check here why it is still pending.

Jay Lorrence
Jay Lorrence

Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.

Articles: 233

Newsletter Updates

Enter your email address below to subscribe to our newsletter

One comment

Comments are closed.